Key opinion leaders emphasize the role of coordinated care between dermatologists and oncologists in monitoring and managing adverse events related to immunotherapy in CSCC and BCC.
This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; Christopher Barker, MD; Omid Hamid, MD; Vishal Patel, MD; and Catherine Pisano, MD.
Barker stated that while radiation toxicities can mimic immunotherapy adverse effects, a large analysis did not find radiotherapy increased immune-related adverse event rates when given within 90 days of immunotherapy initiation. Thus, adverse effects likely represent an additive effect of the 2 modalities rather than synergy. He emphasized the importance of continual cross-disciplinary communication to best attribute causality. Patel advised community providers using immunotherapy to have referral networks in place to manage unfamiliar toxicities. Hamid discussed engaging multidisciplinary care early for recurrent or aggressive skin cancers needing complex resection. Pisano described high-risk features that should trigger medical oncology referral, including rapidly enlarging/painful lesions, multiple in-transit metastases, invasion beyond subcutaneous fat, and perineural invasion on microscopy. She explained that subtle signs like skin fixation can sometimes indicate deep invasion on exam when pathology is pending.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More